NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price, Price Target & More

$6.97 +0.02 (+0.29 %)
(As of 04/23/2018 05:30 AM ET)
Previous Close$6.95
Today's Range$6.87 - $7.03
52-Week Range$1.42 - $8.09
Volume672,700 shs
Average Volume1.80 million shs
Market Capitalization$604.91 million
P/E RatioN/A
Dividend YieldN/A
Beta2.35

About Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARWR
CUSIPN/A
Phone626-304-3400

Debt

Debt-to-Equity Ratio0.03%
Current Ratio3.87%
Quick Ratio3.87%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$31.41 million
Price / Sales19.26
Cash FlowN/A
Price / CashN/A
Book Value$1.08 per share
Price / Book6.45

Profitability

EPS (Most Recent Fiscal Year)($0.47)
Net Income$-34,380,000.00
Net Margins-116.17%
Return on Equity-42.52%
Return on Assets-32.70%

Miscellaneous

Employees93
Outstanding Shares86,790,000

How to Become a New Pot Stock Millionaire

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) posted its earnings results on Friday, February, 9th. The biotechnology company reported ($0.18) EPS for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.04. The biotechnology company had revenue of $3.51 million for the quarter, compared to analyst estimates of $8.71 million. Arrowhead Pharmaceuticals had a negative return on equity of 42.52% and a negative net margin of 116.17%. View Arrowhead Pharmaceuticals' Earnings History.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Arrowhead Pharmaceuticals.

What price target have analysts set for ARWR?

6 brokers have issued 12 month target prices for Arrowhead Pharmaceuticals' stock. Their predictions range from $4.00 to $10.00. On average, they expect Arrowhead Pharmaceuticals' stock price to reach $6.30 in the next twelve months. View Analyst Ratings for Arrowhead Pharmaceuticals.

What are Wall Street analysts saying about Arrowhead Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arrowhead Pharmaceuticals stock:
  • 1. Chardan Capital analysts commented, "We believe that Arrowhead is positioned to achieve a number of significant milestones in 2018. The Company spent most of 2017 quietly regrouping following its announcement in November 2016 that it was discontinuing all of its clinical RNAi programs (ARC-520, ARC-521, and ARC-AAT), which use its dynamic polyconjugate (DPC) delivery technology. The decision to discontinue development of these programs was based on the substantial delays that would have occurred in order to further explore the cause of deaths in a non-clinical toxicology study in non-human primates. Arrowhead subsequently reduced its workforce by approximately 30%. In September 2017, the Company unveiled its new proprietary delivery technology they call Targeted RNAi Molecule (TRiM), along with a portfolio of newly named candidates. Arrowhead’s TRiM delivery technology leverages advances in RNA chemistry and targeting, to deliver a payload with increased potency." (2/19/2018)
  • 2. Cantor Fitzgerald analysts commented, "Arrowhead reiterated its recently disclosed timeline for returning to clinical development with at least two indications (AAT and HBV) in 1H18." (9/25/2017)

Who are some of Arrowhead Pharmaceuticals' key competitors?

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the folowing people:
  • Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 49)
  • Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 52)
  • Dr. Bruce D. Given, Chief Operating Officer (Age 64)
  • Mr. Patrick O'Brien, Gen. Counsel (Age 54)
  • Dr. Mark M. Davis Ph.D., Founder and Founder & Director of Insert Therapeutics Inc & Calando

Has Arrowhead Pharmaceuticals been receiving favorable news coverage?

News articles about ARWR stock have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Arrowhead Pharmaceuticals earned a news impact score of 0.18 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 45.93 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $6.97.

How big of a company is Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals has a market capitalization of $604.91 million and generates $31.41 million in revenue each year. The biotechnology company earns $-34,380,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Arrowhead Pharmaceuticals employs 93 workers across the globe.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]


MarketBeat Community Rating for Arrowhead Pharmaceuticals (ARWR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  366
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Arrowhead Pharmaceuticals in the last 12 months. Their average twelve-month price target is $6.30, suggesting that the stock has a possible downside of 9.61%. The high price target for ARWR is $10.00 and the low price target for ARWR is $4.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.672.502.332.20
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.30$4.70$3.1250$2.00
Price Target Upside: 9.61% downside15.62% downside50.32% downside43.66% downside

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Consensus Price Target History

Price Target History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/27/2018Jefferies GroupInitiated CoverageBuy$10.00HighView Rating Details
2/19/2018Chardan CapitalReiterated RatingBuy$7.00LowView Rating Details
2/12/2018B. RileyBoost Price TargetNeutral -> Neutral$3.00 -> $4.00MediumView Rating Details
2/12/2018Cantor FitzgeraldSet Price TargetNeutral -> Neutral$2.00 -> $5.00MediumView Rating Details
11/27/2017Piper JaffrayUpgradeNeutral -> Overweight$5.50HighView Rating Details
9/18/2017William BlairUpgradeMarket Perform -> OutperformHighView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings History and Estimates Chart

Earnings by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings Estimates

2018 EPS Consensus Estimate: ($0.64)
2019 EPS Consensus Estimate: ($0.94)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.13)($0.13)($0.13)
Q2 20184($0.20)($0.13)($0.17)
Q3 20184($0.20)($0.12)($0.17)
Q4 20184($0.21)($0.13)($0.18)
Q1 20191($0.22)($0.22)($0.22)
Q2 20191($0.23)($0.23)($0.23)
Q3 20191($0.24)($0.24)($0.24)
Q4 20191($0.25)($0.25)($0.25)

Arrowhead Pharmaceuticals (NASDAQ ARWR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018N/AView Earnings Details
2/9/2018Q1 2018($0.14)($0.18)$8.71 million$3.51 millionViewListenView Earnings Details
12/12/2017Q4 2017($0.12)($0.14)$7.32 million$8.71 millionViewN/AView Earnings Details
8/3/2017Q3 2017($0.13)($0.07)$5.29 million$9.34 millionViewListenView Earnings Details
5/3/2017Q2 2017($0.1230)($0.08)$4.19 million$8.99 millionViewListenView Earnings Details
2/6/2017Q117($0.20)($0.17)$13.24 million$4.37 millionViewListenView Earnings Details
12/14/2016Q4 2016($0.33)($0.31)$0.04 million$0.03 millionViewN/AView Earnings Details
8/9/2016Q316($0.37)($0.32)$0.05 million$39.58 millionViewN/AView Earnings Details
5/10/2016Q216($0.37)($0.35)$0.26 million$0.04 millionViewListenView Earnings Details
2/9/2016Q1($0.41)($0.32)$0.29 million$0.04 millionViewN/AView Earnings Details
12/14/2015Q415($0.39)($0.42)$0.14 million$0.04 millionViewListenView Earnings Details
8/4/2015Q315($0.38)($0.27)$0.11 million$0.12 millionViewN/AView Earnings Details
5/11/2015Q214($0.35)($0.33)$110.00 million$43.75 millionViewListenView Earnings Details
2/9/2015Q114($0.32)($0.41)$0.24 million$0.17 millionViewN/AView Earnings Details
11/25/2014Q413($0.25)($0.33)$0.04 million$0.04 millionViewN/AView Earnings Details
8/12/2014Q313($0.22)($0.22)$0.04 million$0.04 millionViewN/AView Earnings Details
5/6/2014Q2 2014($0.18)($0.31)$0.05 million$0.04 millionViewN/AView Earnings Details
2/4/2014Q4($0.18)($0.33)$0.05 million$0.04 millionViewN/AView Earnings Details
12/18/2013Q4($0.23)($0.43)ViewListenView Earnings Details
8/7/2013Q3 2013($0.22)($0.23)$0.50 million$0.04 millionViewN/AView Earnings Details
5/9/2013Q2 2013($0.41)$0.04 millionViewN/AView Earnings Details
2/13/2013Q1 2013($0.33)ViewN/AView Earnings Details
12/20/2012Q4 2012($0.43)ViewN/AView Earnings Details
8/13/2012Q3 2012($0.71)ViewN/AView Earnings Details
5/8/2012Q2 2012($0.44)ViewN/AView Earnings Details
2/9/2012Q1 2012($0.25)ViewN/AView Earnings Details
12/20/2011Q4 2011($0.39)ViewN/AView Earnings Details
8/8/2011Q3 2011($0.20)($0.26)ViewN/AView Earnings Details
5/12/2011Q2 2011($0.20)($0.18)ViewN/AView Earnings Details
2/10/2011Q1 2011($0.20)ViewN/AView Earnings Details
12/22/2010Q4 2010($0.30)($0.28)ViewN/AView Earnings Details
8/12/2010Q3 2010($0.50)($0.06)ViewN/AView Earnings Details
5/13/2010Q2 2010($0.40)($0.33)ViewN/AView Earnings Details
2/11/2010Q1 2010($0.30)ViewN/AView Earnings Details
12/22/2009Q4 2009($0.60)ViewN/AView Earnings Details
8/10/2009Q3 2009($0.60)ViewN/AView Earnings Details
5/15/2009Q2 2009($1.20)ViewN/AView Earnings Details
2/9/2009Q1 2009($1.90)ViewN/AView Earnings Details
12/15/2008Q4 2008($2.14)ViewN/AView Earnings Details
8/11/2008Q3 2008($1.90)ViewN/AView Earnings Details
2/11/2008Q1 2008($1.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Arrowhead Pharmaceuticals (NASDAQ ARWR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 26.85%
Insider Trading History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ ARWR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/27/2018Kenneth Allen MyszkowskiCFOSell20,000$8.00$160,000.00330,815View SEC Filing  
3/15/2018Christopher Richard AnzaloneCEOSell300,000$7.43$2,229,000.002,194,789View SEC Filing  
3/13/2018Christopher Richard AnzaloneCEOSell100,000$7.43$743,000.002,194,789View SEC Filing  
3/5/2018Bruce D GivenCOOSell20,000$6.73$134,600.00908,356View SEC Filing  
1/1/2018Bruce D GivenCOOSell20,000$3.69$73,800.00948,356View SEC Filing  
10/14/2016Douglas B. GivenDirectorSell12,000$6.72$80,640.00View SEC Filing  
8/23/2016Kenneth Allen MyszkowskiCFOSell6,900$8.00$55,200.00128,789View SEC Filing  
8/22/2016Kenneth Allen MyszkowskiCFOSell13,100$8.00$104,800.00128,789View SEC Filing  
12/30/2015Kenneth Allen MyszkowskiCFOSell23,347$6.13$143,117.11135,000View SEC Filing  
10/28/2015Mauro FerrariDirectorBuy400$7.62$3,048.00View SEC Filing  
10/9/2015Mauro FerrariDirectorBuy1,900$6.19$11,761.00View SEC Filing  
1/5/2015David L LewisInsiderSell15,000$8.01$120,150.00View SEC Filing  
10/15/2014Christopher Richard AnzaloneCEOBuy16,000$6.32$101,120.00View SEC Filing  
10/1/2014Charles MckenneyDirectorSell2,500$14.70$36,750.00View SEC Filing  
9/30/2014David L LewisInsiderSell15,000$15.02$225,300.00View SEC Filing  
9/26/2014Douglas B GivenDirectorSell2,000$15.24$30,480.00View SEC Filing  
6/9/2014Charles MckenneyDirectorSell22,000$14.32$315,040.00View SEC Filing  
2/12/2014Kenneth Allen MyszkowskiCFOSell16,000$18.77$300,320.00View SEC Filing  
2/7/2014Edward W FrykmanDirectorSell3,148$15.98$50,305.04View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Arrowhead Pharmaceuticals (NASDAQ ARWR) News Headlines

Source:
DateHeadline
Arrowhead Pharmaceuticals (ARWR) Stock Rating Lowered by BidaskClubArrowhead Pharmaceuticals (ARWR) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 19 at 11:10 AM
Arrowhead Pharmaceuticals (ARWR) Expected to Announce Quarterly Sales of $4.04 MillionArrowhead Pharmaceuticals (ARWR) Expected to Announce Quarterly Sales of $4.04 Million
www.americanbankingnews.com - April 15 at 4:05 AM
Arrowhead Pharmaceuticals: Sneaky Upside Present Over The Course Of 2018Arrowhead Pharmaceuticals: Sneaky Upside Present Over The Course Of 2018
seekingalpha.com - April 13 at 5:19 PM
Arrowhead Pharmaceuticals (ARWR) Expected to Post Earnings of -$0.18 Per ShareArrowhead Pharmaceuticals (ARWR) Expected to Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - April 13 at 11:34 AM
Pre-Open Movers 04/11: (VHC) (LKM) (ARWR) Higher; (BW) (ALOG) (LAYN) Lower (more...)Pre-Open Movers 04/11: (VHC) (LKM) (ARWR) Higher; (BW) (ALOG) (LAYN) Lower (more...)
www.streetinsider.com - April 12 at 9:07 AM
Arrowhead Pharmaceuticals (ARWR) Downgraded to "Buy" at BidaskClubArrowhead Pharmaceuticals (ARWR) Downgraded to "Buy" at BidaskClub
www.americanbankingnews.com - April 10 at 11:29 AM
Arrowhead Pharmaceuticals (ARWR) Lifted to Sell at ValuEngineArrowhead Pharmaceuticals (ARWR) Lifted to Sell at ValuEngine
www.americanbankingnews.com - April 8 at 1:29 PM
Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™
finance.yahoo.com - April 5 at 9:37 AM
Arrowhead Pharmaceuticals (ARWR) Upgraded to Buy at ValuEngineArrowhead Pharmaceuticals (ARWR) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 7:35 PM
Arrowhead Pharmaceuticals Corp (ARWR) Announces Multiple Presentations at The International Liver CongressArrowhead Pharmaceuticals Corp (ARWR) Announces Multiple Presentations at The International Liver Congress
www.streetinsider.com - April 3 at 5:21 PM
Top Stocks Under $10Top Stocks Under $10
www.forbes.com - April 3 at 8:23 AM
Arrowhead Pharmaceuticals Inc (ARWR) Receives Average Recommendation of "Buy" from BrokeragesArrowhead Pharmaceuticals Inc (ARWR) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 1 at 5:48 AM
Brokers Issue Forecasts for Arrowhead Pharmaceuticals Incs Q2 2018 Earnings (ARWR)Brokers Issue Forecasts for Arrowhead Pharmaceuticals Inc's Q2 2018 Earnings (ARWR)
www.americanbankingnews.com - March 29 at 8:19 AM
Traders Buy High Volume of Arrowhead Pharmaceuticals Put Options (ARWR)Traders Buy High Volume of Arrowhead Pharmaceuticals Put Options (ARWR)
www.americanbankingnews.com - March 29 at 6:29 AM
Arrowhead Pharmaceuticals Inc (ARWR) Expected to Post Quarterly Sales of $4.32 MillionArrowhead Pharmaceuticals Inc (ARWR) Expected to Post Quarterly Sales of $4.32 Million
www.americanbankingnews.com - March 29 at 5:42 AM
Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver CongressArrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress
www.finanznachrichten.de - March 28 at 8:16 AM
Insider Selling: Arrowhead Pharmaceuticals Inc (ARWR) CFO Sells 20,000 Shares of StockInsider Selling: Arrowhead Pharmaceuticals Inc (ARWR) CFO Sells 20,000 Shares of Stock
www.americanbankingnews.com - March 27 at 10:33 PM
Can Arrowhead Pharma Keep Up the Pace?Can Arrowhead Pharma Keep Up the Pace?
www.msn.com - March 27 at 5:22 PM
Arrowhead Pharmaceuticals (ARWR) Raised to "Strong-Buy" at BidaskClubArrowhead Pharmaceuticals (ARWR) Raised to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - March 27 at 4:00 PM
-$0.18 EPS Expected for Arrowhead Pharmaceuticals Inc (ARWR) This Quarter-$0.18 EPS Expected for Arrowhead Pharmaceuticals Inc (ARWR) This Quarter
www.americanbankingnews.com - March 27 at 1:14 PM
Arrowhead Pharmaceuticals (ARWR) Coverage Initiated at Jefferies GroupArrowhead Pharmaceuticals (ARWR) Coverage Initiated at Jefferies Group
www.americanbankingnews.com - March 27 at 8:45 AM
Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis BArrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B
finance.yahoo.com - March 27 at 8:20 AM
ValuEngine Upgrades Arrowhead Pharmaceuticals (ARWR) to "Hold"ValuEngine Upgrades Arrowhead Pharmaceuticals (ARWR) to "Hold"
www.americanbankingnews.com - March 25 at 8:45 PM
BidaskClub Upgrades Arrowhead Pharmaceuticals (ARWR) to Strong-BuyBidaskClub Upgrades Arrowhead Pharmaceuticals (ARWR) to Strong-Buy
www.americanbankingnews.com - March 24 at 4:30 PM
Head to Head Review: Actelion (ALIOF) vs. Arrowhead Pharmaceuticals (ARWR)Head to Head Review: Actelion (ALIOF) vs. Arrowhead Pharmaceuticals (ARWR)
www.americanbankingnews.com - March 23 at 9:16 AM
Insider Selling: Arrowhead Pharmaceuticals Inc (ARWR) CEO Sells 100,000 Shares of StockInsider Selling: Arrowhead Pharmaceuticals Inc (ARWR) CEO Sells 100,000 Shares of Stock
www.americanbankingnews.com - March 15 at 7:46 PM
Arrowhead Pharmaceuticals Inc (ARWR) CEO Christopher Richard Anzalone Sells 300,000 SharesArrowhead Pharmaceuticals Inc (ARWR) CEO Christopher Richard Anzalone Sells 300,000 Shares
www.americanbankingnews.com - March 15 at 7:28 PM
Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for ... - Business Wire (press release)Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for ... - Business Wire (press release)
www.businesswire.com - March 13 at 10:05 AM
Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver DiseaseArrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
finance.yahoo.com - March 12 at 5:17 PM
 Brokerages Expect Arrowhead Pharmaceuticals Inc (ARWR) Will Announce Quarterly Sales of $4.32 Million Brokerages Expect Arrowhead Pharmaceuticals Inc (ARWR) Will Announce Quarterly Sales of $4.32 Million
www.americanbankingnews.com - March 12 at 10:26 AM
Zacks Investment Research Weighs in on Arrowhead Pharmaceuticals Incs Q2 2018 Earnings (ARWR)Zacks Investment Research Weighs in on Arrowhead Pharmaceuticals Inc's Q2 2018 Earnings (ARWR)
www.americanbankingnews.com - March 8 at 8:20 AM
Arrowhead Pharmaceuticals Inc (ARWR) Given Consensus Recommendation of "Buy" by BrokeragesArrowhead Pharmaceuticals Inc (ARWR) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 7 at 3:26 AM
Arrowhead to Present at Barclays Global Healthcare Conference 2018Arrowhead to Present at Barclays Global Healthcare Conference 2018
finance.yahoo.com - March 6 at 9:00 AM
Bruce D. Given Sells 20,000 Shares of Arrowhead Pharmaceuticals Inc (ARWR) StockBruce D. Given Sells 20,000 Shares of Arrowhead Pharmaceuticals Inc (ARWR) Stock
www.americanbankingnews.com - March 5 at 9:30 PM
Amgen And Arrowhead Potential Announcement Coming SoonAmgen And Arrowhead Potential Announcement Coming Soon
seekingalpha.com - March 5 at 5:16 PM
OppenheimerFunds Inc. Has $23.18 Million Position in Arrowhead Pharmaceuticals Inc (ARWR)OppenheimerFunds Inc. Has $23.18 Million Position in Arrowhead Pharmaceuticals Inc (ARWR)
www.americanbankingnews.com - March 4 at 12:09 PM
Arrowhead Pharmaceuticals Target of Unusually Large Options Trading (ARWR)Arrowhead Pharmaceuticals Target of Unusually Large Options Trading (ARWR)
www.americanbankingnews.com - February 28 at 6:20 AM
Arrowhead Pharmaceuticals Corp (ARWR) Reports Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver DiseaseArrowhead Pharmaceuticals Corp (ARWR) Reports Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
www.streetinsider.com - February 23 at 8:52 AM
Contrasting Arrowhead Pharmaceuticals (ARWR) & Arcturus Therapeutics (ARCT)Contrasting Arrowhead Pharmaceuticals (ARWR) & Arcturus Therapeutics (ARCT)
www.americanbankingnews.com - February 22 at 5:20 PM
Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver DiseaseArrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
finance.yahoo.com - February 22 at 8:35 AM
Chardan Capital Reiterates "Buy" Rating for Arrowhead Pharmaceuticals (ARWR)Chardan Capital Reiterates "Buy" Rating for Arrowhead Pharmaceuticals (ARWR)
www.americanbankingnews.com - February 20 at 12:24 AM
Arrowhead Pharmaceuticals (ARWR) Downgraded by BidaskClubArrowhead Pharmaceuticals (ARWR) Downgraded by BidaskClub
www.americanbankingnews.com - February 18 at 3:32 PM
Arrowhead Pharmaceuticals Corp (ARWR) Confirms Orphan Drug Status for ARO-AATArrowhead Pharmaceuticals Corp (ARWR) Confirms Orphan Drug Status for ARO-AAT
www.streetinsider.com - February 16 at 5:13 PM
Arrowhead Pharmaceuticals Corp (ARWR) Says it Was Cleared to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis BArrowhead Pharmaceuticals Corp (ARWR) Says it Was Cleared to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B
www.streetinsider.com - February 15 at 5:16 PM
Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis BArrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B
finance.yahoo.com - February 15 at 5:16 PM
Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AATArrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT
finance.yahoo.com - February 15 at 5:16 PM
Brokers Issue Forecasts for Arrowhead Pharmaceuticals Incs FY2018 Earnings (ARWR)Brokers Issue Forecasts for Arrowhead Pharmaceuticals Inc's FY2018 Earnings (ARWR)
www.americanbankingnews.com - February 14 at 11:38 AM
Q2 2018 EPS Estimates for Arrowhead Pharmaceuticals Inc (ARWR) Lifted by AnalystQ2 2018 EPS Estimates for Arrowhead Pharmaceuticals Inc (ARWR) Lifted by Analyst
www.americanbankingnews.com - February 14 at 8:20 AM
William Blair Analysts Raise Earnings Estimates for Arrowhead Pharmaceuticals Inc (ARWR)William Blair Analysts Raise Earnings Estimates for Arrowhead Pharmaceuticals Inc (ARWR)
www.americanbankingnews.com - February 14 at 8:20 AM
Cantor Fitzgerald Analysts Give Arrowhead Pharmaceuticals (ARWR) a $5.00 Price TargetCantor Fitzgerald Analysts Give Arrowhead Pharmaceuticals (ARWR) a $5.00 Price Target
www.americanbankingnews.com - February 12 at 11:18 PM

SEC Filings

Arrowhead Pharmaceuticals (NASDAQ:ARWR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Arrowhead Pharmaceuticals (NASDAQ ARWR) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.